There are two types of biotech stocks, says Dewey Steadman, who heads up investor relations for United Therapeutics.
United Therapeutics Corp, a biotechnology firm, focuses on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. Over the past year, Christopher Causey has engaged in multiple transactions, selling a total of 12,640 shares and purchasing none. Shares of United Therapeutics Corp were priced at $304.18 on the day of the sale.
Director Judy Olian sold 1,700 shares of United Therapeutics Corp (NASDAQ:UTHR) on June 17, 2024, as reported in a recent SEC Filing.